Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study (Q46720863)
Jump to navigation
Jump to search
scientific article published in March 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study |
scientific article published in March 2008 |
Statements
1 reference
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study (English)
1 reference
1 reference
Suresh Ramalingam
1 reference
Judy Forster
1 reference
Cynthia Naret
1 reference
Terry Evans
1 reference
Matt Sulecki
1 reference
Haolan Lu
1 reference
Paola Teegarden
1 reference
Martin R Weber
1 reference
1 March 2008
1 reference
3
1 reference
3
1 reference
258-264
1 reference